OGN Q4 2025

Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Organon closed out 2025 on a difficult note, with fourth-quarter results falling short on both the top and bottom lines as a $301 million non-cash goodwill impairment charge tied to underperforming U.S. Products dominated the headline story. Adjusted… Read more Organon closed out 2025 on a difficult note, with fourth-quarter results falling short on both the top and bottom lines as a $301 million non-cash goodwill impairment charge tied to underperforming U.S. Products dominated the headline story. Adjusted EPS came in at $0.63, missing the $0.76 consensus estimate by 17.11%, while revenue of $1.51 billion edged just below the $1.52 billion consensus and declined 5.3% year over year. The impairment swung Q4 to a GAAP net loss of $205 million, against net income of $109 million a year earlier. Women's Health, the company's flagship franchise, bore considerable weight as Nexplanon revenue dropped 20% on a constant-currency basis, pressured by U.S. Policy-related access restrictions and roughly $17 million in lost wholesaler sales. Biosimilars offered a rare bright spot, growing 11% on the strength of Hadlima and newly launched assets. Looking ahead, Organon guided for approximately $6.20 billion in 2026 revenue and roughly $1.90 billion in adjusted EBITDA, both essentially flat with 2025, while a recently announced licensing deal for a hormone-free copper IUD signals continued investment in rebuilding its women's health portfolio.